The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://declanksfy880584.bloggazzo.com/37652826/retatrutide-vs-tirzepatide-a-comparative-analysis